Clinical Trials & Research

In the body, crystals – made of things such as calcium or a collection of urine – form masses that can cause pain and serious health conditions. A University of Houston crystals expert, Jeffrey Rimer, Abraham E. Dukler Professor of Chemical Engineering, known globally for his seminal breakthroughs using innovative methods to control crystals to
0 Comments
A recent study from UiB shows that elevated plasma methylmalonic acid predicts increased risk of acute myocardial infarction and mortality in patients with suspected or verified coronary heart disease. Methylmalonic acid (MMA) is a substance produced from the breakdown of aminoacids, odd-chain fatty acids and cholesterol in the body. MMA concentration in blood is reported
0 Comments
The hormone kisspeptin could be used to treat women and men distressed by their low sexual desire, according to two new studies. The studies, both published in JAMA Network Open, found that giving kisspeptin can boost sexual responses in women and men who have hypoactive sexual desire disorder (HSDD) – a condition characterized by low
0 Comments
A team of researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) and Massachusetts General Hospital (MGH) has developed a soft robotic wearable capable of significantly assisting upper arm and shoulder movement in people with ALS. Some 30,000 people in the U.S. are affected by amyotrophic lateral sclerosis (ALS), also
0 Comments
Thought LeadersThe Institute of Cancer TherapeuticsThe University of Bradford To commemorate World Cancer Day, we spoke to a multidisciplinary team of researchers from The Institute of Cancer Therapeutics (ICT) based at the University of Bradford about their work in cancer research.  Please can you introduce yourself and tell us about your professional background and current
0 Comments
Coherent Corp., a leader in laser processing systems, today announced the introduction of its AP 530 S, a fully automated laser system for texturing and marking implantable medical devices. Image Credit: Coherent Corp. Advances in materials and technologies for implanted medical devices, combined with the aging of the global population, are driving the urgency for
0 Comments
SEATTLE and BRISBANE, Australia, Feb. 2, 2023. Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the publication of a study in Scientific Reports, a journal in the Nature portfolio, validating the use of SeptiCyte RAPID as a triaging tool for COVID-19 patients requiring hospitalization and potentially
0 Comments
Despite evidence showing that the causes of medication errors can be traced back to multiple factors in the healthcare setting, healthcare professionals still often feel the blame on them. In a new study, healthcare professionals described a variety of negative emotions when reporting medication administration errors, most commonly feelings of fear, disturbed mood, sadness, and
0 Comments
CARLSBAD, Calif., Feb. 1, 2023. Ionis Pharmaceuticals, Inc. today announced that GSK has initiated two randomized, double-blind, placebo-controlled Phase 3 studies evaluating the safety and efficacy of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense medicine for the treatment of patients with chronic hepatitis B infection (CHB). “The initiation of this Phase 3 program is an important
0 Comments
Most cancer diagnostic techniques rely on uncomfortable and invasive procedures, such as biopsies, endoscopies or mammograms. Blood samples could be a less unpleasant option, though only a few forms of the disease can currently be diagnosed this way. But now, researchers reporting in ACS Sensors have developed an easy-to-use method that can detect small amounts
0 Comments
A new study led by scientists at The Neuro (Montreal Neurological Institute-Hospital) of McGill University finds a correlation between neurodegeneration in obese people and Alzheimer’s disease (AD) patients, suggesting that losing excess weight could slow cognitive decline in aging and lower risk for AD. Previous research has shown that obesity is linked with Alzheimer’s disease
0 Comments
HAYWARD, Calif., Jan. 23, 2023. Benitec Biopharma Inc. (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced the enrollment of the first oculopharyngeal muscular dystrophy (OPMD) patient into the OPMD natural history phase of the BB-301 clinical development program.
0 Comments
TORONTO, Jan. 24, 2023. Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental health, is pleased to announce it has received Health Canada approval to begin a Phase 2 clinical trial evaluating the safety, tolerability and efficacy of repeat low-doses of psilocybin for the
0 Comments
BOSTON and ATLANTA, Jan. 25, 2023. Inhibikase Therapeutics, Inc. (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the publication of studies describing the potential of IkT-148009 as a disease-modifying therapy for Parkinson’s
0 Comments
26 January 2023 — The US Food and Drug Administration (FDA) has stated that AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab) is not currently authorised for Emergency Use for pre-exposure prophylaxis (prevention) of COVID-19 in the US until further notice, due to the sustained high frequency of circulating SARS-CoV-2 variants that Evusheld does not retain in
0 Comments
STOCKHOLM, Jan. 26, 2023. Pivotal study data published in The New England Journal of Medicine (NEJM) continues to highlight the efficacy, safety, and pharmacokinetic profile of efanesoctocog alfa (formerly BIVV001), a potential new medicine for haemophilia A. These data demonstrate the clinical benefits of normal to near-normal factor activity levels (>40%) for the majority of
0 Comments
RARITAN, N.J., Jan. 27, 2023. The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant
0 Comments
Designation based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults CAMBRIDGE, MA / ACCESSWIRE / January 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines,
0 Comments
TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE) January 30, 2023 –Daiichi Sankyo (TSE: 4568) today announced that the first patient has been dosed in the global, randomized TROPION-Lung07 phase 3 trial evaluating datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy, in patients with previously untreated advanced or metastatic non-squamous non-small cell lung
0 Comments
SAN DIEGO and TORONTO, Jan. 30, 2023. Aptose Biosciences Inc. (“Aptose”) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnostic tyrosine kinase inhibitor (TKI) being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (R/R AML).
0 Comments
Testing plays a crucial role in humanity’s strategy to mitigate the effects of widespread COVID-19 infection. However, given multiple options for testing and the emergence of the highly contagious Omicron variant, how do we choose which test to use? A study led by Osaka University recently found that the sensitivity of rapid antigen tests (RATs)
0 Comments
A collaborative team from the Terasaki Institute for Biomedical Innovation (TIBI) has developed a contact lens prototype that is specifically designed to prevent contact lens-induced dry eye (CLIDE). The lens alleviates this condition by facilitating tear flow in response to normal eye blinking. This approach can relieve the discomfort, visual impairment, and risk of inflammation
0 Comments
Anesthesiologists can play a role in reducing the greenhouse gas emissions that contribute to global warming by decreasing the amount of anesthetic gas provided during procedures without compromising patient care, suggests new research being presented at the American Society of Anesthesiologists’ ADVANCE 2023, the Anesthesiology Business Event. Inhaled anesthetics used during general anesthesia are estimated
0 Comments
The vital role of oxytocin-;the “love hormone”-;for social attachments is being called into question. More than forty years of pharmacological and behavioral research has pointed to oxytocin receptor signaling as an essential pathway for the development of social behaviors in prairie voles, humans, and other species, but a genetic study publishing in the journal Neuron
0 Comments
A nerve stimulation therapy developed at Columbia University Vagelos College of Physicians and Surgeons is showing promise in animal studies and may eventually allow people with spinal cord injuries to regain function of their arms. “The stimulation technique targets the nervous system connections spared by injury,” says Jason Carmel, MD, PhD, a neurologist at Columbia
0 Comments